Literature DB >> 22168652

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

Robert Rosenstein, David Parra.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22168652     DOI： 10.1056/NEJMc1112233

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  4 in total

Review 1.  Adverse Outcomes from Atrial Fibrillation;Mechanisms, Risks, and Insights Learned from Therapeutic Options.

Authors:  David L Johnson; John D Day; Srijoy Mahapatra; T Jared Bunch
Journal:  J Atr Fibrillation       Date:  2012-02-02

Review 2.  Rivaroxaban: a review of its use in the prevention of stroke and systemic embolism in patients with atrial fibrillation.

Authors:  Natalie J Carter; Greg L Plosker
Journal:  Drugs       Date:  2013-05       Impact factor: 9.546

3.  Time in therapeutic range: Warfarin anticoagulation for atrial fibrillation in a community-based practice.

Authors:  Derek Gateman; Melissa Elizabeth Trojnar; Gina Agarwal
Journal:  Can Fam Physician       Date:  2017-10       Impact factor: 3.275

Review 4.  Novel Anticoagulants in Atrial Fibrillation: Monitoring, Reversal and Perioperative Management.

Authors:  Fadi Shamoun; Hiba Obeid; Harish Ramakrishna
Journal:  Biomed Res Int       Date:  2015-07-02       Impact factor: 3.411
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.